JBCHEPHARM

March 14 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:

• USFDA INSPECTION OF COMPANY’S API MANUFACTURING FACILITY – D9 AT PANOLI, GUJARAT

• FACILITY RECEIVED “NO OBSERVATIONS” AND THUS NO FORM 483 WAS ISSUED

Source text: [ID:]

Further company coverage: JBCH.NS

(([email protected];))

Feb 19 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:

• J B CHEMICALS AND PHARMACEUTICALS - GOT TAX ORDER FOR DEMAND OF 6.8 MILLION RUPEES

Source text: ID:nNSE9db9Rl

Further company coverage: JBCH.NS

(([email protected];;))

** J.B. Chemicals and Pharmaceuticals JBCH.NS rises as much as 2.7% to 1,789.95 rupees; set for second straight session of gains

** Co reports ~22% y/y rise in Q3 consol net profit, helped by sustained domestic demand for its drugs used to treat chronic and acute conditions

** Rev from ops grows 14% y/y

** Stock rated "buy" on avg; median PT is 2,230 rupees - LSEG

** JBCH cuts YTD losses to 5.5%

($1 = 87.1170 Indian rupees)

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

Feb 4 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:

• JB CHEMICALS - GETS TAX ORDER WITH DEMAND OF 3.5 MILLION RUPEES

Source text: [ID:]

Further company coverage: JBCH.NS

(([email protected];))

Jan 16 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:

• DEMAND OF 8.1 MILLION RUPEES FOR MISMATCH IN INPUT TAX CREDIT

Source text: ID:nBSE4NZJ5D

Further company coverage: JBCH.NS

(([email protected];;))

Nov 6 (Reuters) -

• KKR IS SAID TO CONSIDER SELLING $750 MILLION STAKE IN JB PHARMA- BLOOMBERG NEWS

Source text: https://tinyurl.com/223cgvue

(([email protected];))

Oct 1 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:

• APPROVED CAPACITY ADDITION TO IV MANUFACTURING FACILITY AT PANOLI

• ESTABLISHMENT OF DEDICATED MANUFACTURING LINE FOR POVIDONE/IODINE LIQUID, OINTMENT

• INVESTMENT REQUIRED FOR IV MANUFACTURING EXPANSION AT 494.9 MILLION RUPEES

• INVESTMENT REQUIRED FOR MANUFACTURING LINE AT 215.5 MILLION RUPEES

Source text for Eikon: ID:nBSE4nSYTm

Further company coverage: JBCH.NS

(([email protected];;))

Aug 8 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:

• Q1 CONSOL NET PROFIT 1.77 BILLION RUPEES; IBES PROFIT EST. 1.65 BILLION RUPEES

• Q1 CONSOL REVENUE FROM OPERATIONS 10.04 BILLION RUPEES; IBES EST. 10.16 BILLION RUPEES

Source text for Eikon: ID:nBSE2gJSYk

Further company coverage: JBCH.NS

(([email protected];))

- Source link: (https://shorturl.at/Bb3Nq)

- Note: Reuters has not verified this story and does not vouch for its accuracy

(Bengaluru newsroom)

(([email protected]; +91 80 6749 1310;))

Repeats for wider distribution with no changes to text

MUMBAI/BENGALURU, May 6 (Reuters) - Global investment firm KKR KKR.N will buy Indian medical devices maker Healthium Medtech HEAT.NS from UK-based Apax Partners in a deal that three sources with direct knowledge of the matter say is valued at 70 billion rupees ($838.60 million).

Healthium and Apax did not immediately respond to Reuters' requests seeking comment, while KKR declined to comment.

KKR will acquire Healthium through a special purpose vehicle - owned by KKR-managed funds - that will have a controlling interest in Healthium group, including Healthium Medtech, the three companies said in a statement.

The acquisition marks KKR's latest investment in the Indian healthcare sector, with the firm already holding stakes in Indian drugmaker J B Chemicals and Pharmaceuticals JBCH.NS, hospital chain operator Max Healthcare MAXE.NS and generic injectables maker Gland Pharma GLAD.NS.

Private equity firm Apax bought Healthium, which is involved in the manufacturing of products used in surgical, post-surgical, and chronic care procedures, in 2018.

($1 = 83.4725 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru, M. Sriram in Mumbai, Kane Wu in Hong Kong; Editing by Janane Venkatraman )

(([email protected]; 8800437922;))

April 29 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:

• J B CHEMICALS AND PHARMACEUTICALS - GOT TAX ORDER FOR DEMAND OF 3.1 MILLION RUPEES

Source text for Eikon: ID:nNSE5F12gL

Further company coverage: JBCH.NS

(([email protected];))

- Source link: (https://bityl.co/P5hQ)

- Note: Reuters has not verified this story and does not vouch for its accuracy

(Bengaluru newsroom)

(([email protected]; +91 80 6749 1310;))

** Shares of JB Chemicals and Pharmaceuticals JBCH.NS extend losses from yesterday, currently down 5.5% at 1,511.75 rupees

** Top shareholder KKR mulls selling controlling stake in co, Bloomberg reported on Wednesday, citing people familiar with the matter

** Stock closed almost 3% lower Wednesday

** JBCH declined to comment, KKR did not immediately respond to Reuters' requests

** Avg analyst rating is "buy"; median PT is 1,720.5 rupees - LSEG data

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

** Shares of JB Chemical and Pharmaceuticals Ltd JBCH.NS end 3% lower at 1,600.2 rupees

** Top shareholder KKR mulls selling controlling stake in co, Bloomberg reports, citing people familiar with the matter

** JBCH was down about 0.4% before the report

** Co, KKR did not immediately respond to Reuters requests for comment

** KKR via Tau Investment Holdings owns 53.8% stake in co, stake sale at early stage - report

** Eleven analysts tracking JBCH rate it "buy" on avg; median PT is 1,720.5 rupees - LSEG data

** Stock down 5% this month

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

** Shares of J B Chemicals and Pharmaceuticals JBCH.NS rise as much as 12.5% to all-time high of 1,940 rupees

** Indian drugmaker reported ~26% YoY rise in Dec-qtr consol net profit on strong domestic and overseas demand

** Stock last up 4.5%, set for sixth straight session of gains

** Volume tops 1.7 mln shares in heavy trading, 12.7x the 30-day moving avg

** Avg rating of 11 analysts on JBCH at "buy"; median PT is 1,655.50 rupees - LSEG data

** JBCH rose 67% in 2023, posting its fifth straight yearly gain

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

BENGALURU, Feb 6 (Reuters) - India's J B Chemicals and Pharmaceuticals JBCH.NS reported its sixth straight quarter of profit rise on Tuesday, led by strong demand in its domestic and international markets.

The company's consolidated net profit was 1.34 billion rupees (nearly $16 million) for the quarter ended Dec. 31, compared with 1.06 billion rupees a year earlier.

The Mumbai-based company's sales have benefitted from a series of acquisitions involving companies with portfolios of cardiovascular and ophthalmology drugs. Moreover, sales were boosted by new product launches.

J B Chemicals, known for manufacturing generic drugs and herbal lozenges used to soothe irritated throats, said its revenue from operations rose 6.6% to 8.45 billion rupees.

Revenue growth was fuelled by a 14% increase in its domestic business, its largest market, and a 6% rise in overseas business, including the Russian and South African markets.

The company did not give a region-wise revenue break up.

J B Chemicals' results follow those of larger generic drugmakers such as Cipla CIPL.NS, Dr Reddy's REDY.NS and Sun Pharma SUN.NS, all of which beat their third-quarter profit estimates on robust U.S. sales.

($1 = 83.0429 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Dhanya Ann Thoppil)

(([email protected];))

Dec 25 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:

• J B CHEMICALS AND PHARMACEUTICALS - GOT TAX DEMAND OF 4.6 MILLION RUPEES

Further company coverage: JBCH.NS

(([email protected];))

Dec 19 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:

• APPROVED EXECUTION OF TRADE MARK LICENSE AGREEMENT WITH NOVARTIS INNOVATIVE THERAPIES AG

• APPROVED PROMOTION AND DISTRIBUTION AGREEMENT WITH NOVARTIS HEALTHCARE

Source text for Eikon: ID:nNSE9N4LZt

Further company coverage: JBCH.NS

(([email protected];))

Dec 5 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:

• LAKSHAY KATARIA CEASED TO BE CHIEF FINANCIAL OFFICER

Source text for Eikon: ID:nBSET0w00

Further company coverage: JBCH.NS

(([email protected];))

** Shares of JB Chemicals and Pharmaceuticals JBCH.NS rise as much as 4.60% to a record high of 1,529.50 rupees

** Pharma co posts 36% Y/Y rise in net profit to 1.51 bln rupees ($18.14 mln) in Sept-quarter; rev from ops up 9%

** Strong India and contract development and manufacturing organisation (CDMO) outlook are key positives for JBCH - Jefferies

** Raises TP to 1,680 rupees from 1,555 rupees, implying 16% upside for stock in next 12 months

** Trading volume is twice as much as 30-day avg, as of 11:37 a.m. IST - LSEG data

** Of 13 analysts tracking JBCH, five maintain "strong buy", six "buy" and two "hold"; median TP is 1,508.75 rupees

** JBCH up 57% YTD, including today's gains

($1 = 83.2550 Indian rupees)

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Nov 7 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:

• INDIA'S J B CHEMICALS AND PHARMACEUTICALS SEPT-QUARTER CONSOL NET PAT 1.51 BILLION RUPEES VERSUS PROFIT 1.11 BILLION RUPEES

• J B CHEMICALS AND PHARMACEUTICALS SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 8.82 BILLION RUPEES VERSUS 8.09 BILLION RUPEES

Source text for Eikon: ID:nBSEZB4BG

Further company coverage: JBCH.NS

(([email protected];;))

** Shares of J. B. Chemicals & Pharmaceuticals JBCH.NS down as much as 4.08% to 1244.45 rupees, their lowest since Aug. 3

** Pharma co says officers of Maharashtra Goods and Services Tax Department commenced inspection on co's premises

** Business operations will not be impacted, says co

** Analysts' average rating is equivalent of "buy", their median PT is 1,470.5 rupees

** Stock last down 2.7%, trimming YTD gains to ~29%

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

Sept 7 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:

• CFO LAKSHAY KATARIA RESIGNS

Source text for Eikon: ID:nBSE63vfnS

Further company coverage: JBCH.NS

(([email protected];;))

** Shares of J.B. Chemicals & Pharmaceuticals Ltd JBCH.NS rise as much as 5.1% to 2,785 rupees, reversing two sessions of losses

** Active pharmaceutical ingredients (API)-maker says US FDA approved co's generic drug used for treatment of anxiety and depression

** Drug had estimated annual sales $23.90 mln in the US - JBCH in a statement

** Stock trading above its 50-, 100-, and 200-day moving averages since May 29, in bullish trend

** Trading volume at ~175,400 shares as of 12:40 p.m. IST, 1.5x the 30-day avg of ~118,700 shares

** Average rating of 14 analysts is equivalent of 'buy'; median PT is 2,822 rupees - Refinitiv data

** Stock last up ~41.5% so far this year

(Reporting by Biplob Kumar Das in Bengaluru)

(([email protected]))

** Shares of J B Chemicals and Pharmaceuticals Ltd JBCH.NS up as much as 13.2% to record high of 2,773.95 rupees

** Stock on track to rise for third straight session

** Kotak Institutional Equities and IIFL Securities identify JBCH as one of the cos to lead India growth momentum in Q1FY24

** JBCH likely to continue outperforming industry growth in Q1 led by robust growth in chronic therapies; to post 10%-12% Y/Y organic growth in India business - IIFL Securities

** Despite short-term impact of delayed monsoons, domestic pharma market growth resilient; expect India formulations revenue to clock over 11% CAGR over FY23-26 - brokerages

** Over 737,000 shares change hands by 01:06 p.m. IST, 9.5x the 30-day moving avg

** 12 analysts have a "buy" or "strong buy" rating, two rate it "hold"; median PT is 2,387.50 rupees - Refinitiv data

** As of last close, stock up 26% this year

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** Shares of JB Chemicals and Pharmaceuticals JBCH.NS rise as much as 4.30% to a record high of 2,447.75 rupees

** Global brokerage Jefferies initiates coverage on the domestic drug maker with a "buy" recommendation

** Jefferies sets target price at 2,680 rupees, an implied upside of 19%

** Synergistic acquisitions, new launches to aid JBCH to outperform industry growth - Jefferies

** Estimates revenue CAGR (compound annual growth rate) of 13% to 23.7 bln rupees over FY2023-FY2026

** Trading volume is 185,834 shares at 12:18 p.m. IST, twice the 30-day avg - Refinitiv data

** Relative strength index of JBCH has been above 70 since June 19, suggesting that the stock may be overbought

** Of the 14 analysts tracking co, six maintain "strong buy", six suggest "buy" and two recommend "hold"; median TP is 2,387.50 rupees - Refinitiv data

** Stock has gained over 24% in 2023 so far vs 5% rise in pharma index .NIPHARM

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

June 12 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:

• J B CHEMICALS AND PHARMACEUTICALS LTD - CO'S FORMULATIONS MANUFACTURING FACILITY- T20 AT PANOLIWAS INSPECTED BY USFDA

• J B CHEMICALS AND PHARMACEUTICALS LTD - INSPECTION WAS CONDUCTED FROM JUNE 5 TO JUNE 9

• J B CHEMICALS AND PHARMACEUTICALS LTD - FACILITY RECEIVED "NO OBSERVATIONS" AND THUS NO FORM 483 WAS ISSUED

Source text for Eikon: ID:nBSE6wnrvk

Further company coverage: JBCH.NS

(([email protected];))

By M. Sriram and Yantoultra Ngui

MUMBAI/SINGAPORE, June 1 (Reuters) - KKR & Co KKR.N is moving a managing director from India to Singapore to lead the firm's Southeast Asia private equity business, two familiar with the matter sources told Reuters, bolstering its personnel in the region.

Prashant Kumar, who has been with KKR in Mumbai since 2018, will move to Singapore and start his new role in July, one of the sources said.

Kumar will work with Ashish Shastry, a partner who heads Southeast Asia and co-heads the firm's Asia Pacific Private Equity business.

A spokesperson for KKR declined to comment.

Kumar, an alumnus of The Wharton School and the Indian Institute of Technology, has invested in Indian companies including deodorant-maker Vini Cosmetics and drug-maker JB Chemicals.

Kumar's move comes after KKR has bolstered its Indian leadership in recent years. It hired Gaurav Trehan from fellow buyout firm TPG Inc TPG.O in 2020 to lead its Indian business.

Last month, KKR also hired Trehan's former colleague Akshay Tanna from TPG to be a partner in its Indian private equity team, said a source with direct knowledge of the matter.

The move also comes as KKR strengthens its presence in India and Southeast Asia. It raised $15 billion for its fourth Asia-Pacific focused private equity fund in 2021, one of the region's largest for the asset class.

KKR has been investing in Southeast Asia since 2005, and opened its Singapore office in 2012. Its investments in the region include private equity, real estate, credit and infrastructure.

In March, KKR-backed telecom tower platform Frontier Tower Associations bought more than a 100 telecom towers in the Philippines from broadband group PLDT for $220 million.

Reuters reported last week that hospital chain Aster DM Healthcare ATRD.NS and its advisers had reached out to KKR to hold talks over a stake sale.

(Reporting by M. Sriram in Mumbai and Yantoultra Ngui in Singapore Editing by Kane Wu and Mark Potter)

(([email protected];; Reuters Messaging: Twitter: @followthemani))

May 24 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:

• APPROVED SUB-DIVISION OF EXISTING EQUITY SHARES

• SPLIT OF SHARES IN 1:2 RATIO

• FINAL DIVIDEND OF 9.25 RUPEES PER SHARE

Source text for Eikon: ID:nBSE49NTLq

Further company coverage: JBCH.NS

(([email protected];))

May 8 (Reuters) - J B Chemicals and Pharmaceuticals Ltd JBCH.NS:

• J B CHEMICALS AND PHARMACEUTICALS LTD - TO CONSIDER SUB-DIVISION OF EQUITY SHARES OF COMPANY

Source text for Eikon: ID:nBSE4dVGF8

Further company coverage: JBCH.NS

(([email protected];))